Production (Stage)
X4 Pharmaceuticals, Inc.
XFOR
$3.10
-$0.13-4.03%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 282.00K | -39.82M | -36.70M | 90.83M | -51.77M |
| Total Depreciation and Amortization | 476.00K | 273.00K | 267.00K | 194.00K | 62.00K |
| Total Amortization of Deferred Charges | 225.00K | 201.00K | 194.00K | 207.00K | 254.00K |
| Total Other Non-Cash Items | -10.07M | 5.16M | 3.86M | -122.56M | 15.76M |
| Change in Net Operating Assets | -3.28M | 1.20M | -1.66M | 1.05M | 2.09M |
| Cash from Operations | -12.37M | -33.00M | -34.03M | -30.28M | -33.60M |
| Capital Expenditure | -- | -41.00K | -92.00K | -134.00K | -59.00K |
| Sale of Property, Plant, and Equipment | -- | 0.00 | 0.00 | 105.00M | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -3.14M | -8.58M | -15.84M | -8.00M | -5.26M |
| Cash from Investing | -3.14M | -8.62M | -15.93M | 96.86M | -5.32M |
| Total Debt Issued | -- | 0.00 | 0.00 | 20.00M | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 135.00K | 0.00 | 159.00K | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 135.00K | 0.00 | 20.16M | -- |
| Foreign Exchange rate Adjustments | 72.00K | -244.00K | 165.00K | -18.00K | -59.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -15.43M | -41.73M | -49.80M | 86.73M | -38.98M |